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Objectives The primary objective of this multicenter registry was to study the prognostic value of positron emission tomog-
raphy (PET) myocardial perfusion imaging (MPI) and the improved classification of risk in a large cohort of pa-
tients with suspected or known coronary artery disease (CAD).
Background Limited prognostic data are available for MPI with PET.
Methods A total of 7,061 patients from 4 centers underwent a clinically indicated rest/stress rubidium-82 PET MPI, with a
median follow-up of 2.2 years. The primary outcome of this study was cardiac death (n  169), and the second-
ary outcome was all-cause death (n  570). Net reclassification improvement (NRI) and integrated discrimina-
tion analyses were performed.
Results Risk-adjusted hazard of cardiac death increased with each 10% myocardium abnormal with mildly, moderately,
or severely abnormal stress PET (hazard ratio [HR]: 2.3 [95% CI: 1.4 to 3.8; p  0.001], HR: 4.2 [95% CI: 2.3 to
7.5; p  0.001], and HR: 4.9 [95% CI: 2.5 to 9.6; p  0.0001], respectively [normal MPI: referent]). Addition of
percent myocardium ischemic and percent myocardium scarred to clinical information (age, female sex, body
mass index, history of hypertension, diabetes, dyslipidemia, smoking, angina, beta-blocker use, prior revascular-
ization, and resting heart rate) improved the model performance (C-statistic 0.805 [95% CI: 0.772 to 0.838] to
0.839 [95% CI: 0.809 to 0.869]) and risk reclassification for cardiac death (NRI 0.116 [95% CI: 0.021 to
0.210]), with smaller improvements in risk assessment for all-cause death.
Conclusions In patients with known or suspected CAD, the extent and severity of ischemia and scar on PET MPI provided
powerful and incremental risk estimates of cardiac death and all-cause death compared with traditional coronary
risk factors. (J Am Coll Cardiol 2013;61:176–84) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.043Several studies have demonstrated the prognostic value of
positron emission tomography (PET) myocardial perfusion
imaging (MPI) (1–7) using conventional metrics (signifi-
cant hazard ratio [HR] in multivariable risk-adjusted mod-
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Although these conventional metrics have demonstrated a
strong and independent association between abnormal MPI
and adverse clinical outcomes, the metrics involved rela-
tively small single-center studies and were limited in deter-
mining the clinical utility of PET MPI. The clinical utility
of a risk marker is its ability to reclassify risk when added to
the traditional risk model. Improved risk reclassification will
allow us to make clinical decisions that may lead to changes
in management and clinical outcomes. Therefore, the aim of
our study was to determine the incremental prognostic value
and clinical utility of rest and stress perfusion defects on
PET MPI over clinical risk factors using the traditional and
novel metrics of risk reclassification in a large number of
patients with known or suspected coronary artery disease
(CAD) from a large multicenter PET registry.
Methods
Registry methods. Four centers participated in this multi-
center PET registry and enrolled 7,061 patients. Each
center enrolled patients clinically referred for a pharmaco-
logical stress rubidium-82 (Rb-82) MPI. Data from some of
the patients (n  3,884) were included in prior publications
2,4,6,8,9). Each center had institutional review board
pproval for the study. Study methods are shown in greater
etail in the Appendix section.
PI methods. Patients were instructed to refrain from
affeine intake for at least 12 h prior to the vasodilator study.
ach patient underwent Rb-82 MPI using a dedicated or
ybrid PET/computed tomography (CT) scanner with
ite-specific protocols.
ollow-up methods. Cardiac death was the primary end-
point and all-cause death the secondary endpoint of this
study. During follow-up, 3 of the 4 centers ascertained the
cause of death and identified 169 cardiac deaths in 6,037
patients (2.9%, 2.9%, and 2.2% at each site). This cohort
was used for the analyses of the primary endpoint, cardiac
death. All-cause death (n  570) was studied in 7,061
atients from 4 sites (9.8%, 8.2%, 9.2%, and 3.9% at each
ite). The median duration of follow-up for the entire
ohort was 2.2 years (interquartile range: 1.3 to 3.3 years).
tatistical analysis. We used standardized approaches to
ata analysis including comparisons of categorical variables
ith chi-square statistics and Student t tests for continuous
easures.
SURVIVAL ANALYSES AND PROGNOSTIC VALUE. Univariable
associations of clinical and PET variables with death out-
comes were evaluated using Cox proportional hazard mod-
els. Kaplan-Meier survival curves were plotted.
In our multivariable Cox model, we examined the unique
increase in the relative hazard for cardiac death and all-cause
death by percent scarred and percent ischemic perfusion
abnormalities on MPI. All variables for the Cox models
were chosen a priori and included age, coronary risk factors, Pmedication use, and symptoms
on presentation, along with the
PET data.
ANALYSES FOR INCREMENTAL
PROGNOSTIC VALUE AND RISK
RECLASSIFICATION. Predicted
ardiac death from each Cox
odel was subdivided into 3 cat-
gories using the previously es-
ablished risk thresholds of
1%/year, 1% to 2.9%/year, and
3%/year (event rates at 2 years
f follow-up are shown in the
esults) (10). Predicted all-cause
eath was subdivided into 3 cat-
gories including 2.5%/year, 2.5% to 7.4%/year, and
7.5%/year (event rates at 2 years of follow-up are shown in
he results). Higher-risk thresholds were used for all-cause
eath based on the distribution of cardiac deaths and
ll-cause deaths in the 6,037 patients with both events
ecorded. The net reclassification improvement (NRI)
ethodologies of Pencina et al. (11) were applied, including
oth categorical and continuous estimates, using SAS
ethods for calculating the NRI for survival data (11,12). In
,102 patients with rest left ventricular ejection fraction
LVEF) data, we explored the incremental prognostic value
f PET MPI versus a clinical model incorporating rest
VEF.
esults
he baseline demographics and risk factors stratified by
ategories of percent myocardium abnormal at stress are
isted in Table 1. The percent of normal scans in this
egistry was 44% (47%, 40%, 57%, and 41% for each of the
ites in this registry).
nivariable associations among cardiovascular risk factors,
b-82 PET MPI and outcomes. The univariable clinical
nd PET MPI predictors of cardiac death and all-cause
eath are listed in Table 2 and Online Table 1. The percent
yocardium abnormal, percent myocardium ischemic,
nd percent myocardium scarred were significant univari-
ble predictors of cardiac death and all-cause death
Figs. 1A and 1B).
ultivariable Cox models for the estimation of cardiac
eath. The independent predictors of cardiac death (n 
,037) (Table 3) and all-cause death (n  7,061) (Online
able 2) were determined using separate multivariable Cox
roportional hazard models. The percent myocardium isch-
mic and percent myocardium scarred were independent
redictors of cardiac death and all-cause death. For each
0% increase in percent myocardium ischemic and percent
yocardium scarred, the hazard of cardiac death increased
y 34% and 57%, respectively. After adjustment for the
isted covariates, compared with patients with normal stress
Abbreviations
and Acronyms
CAD  coronary artery
disease
IDI  integrated
discrimination improvement
LVEF  left ventricular
ejection fraction
MPI  myocardial perfusion
imaging
NRI  net reclassification
improvement
PET  positron emission
tomographyET MPI, the relative hazard of cardiac death was 2.3 (95%
tion; M
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0.001), and 4.9 (95% CI: 2.5 to 9.6; p  0.0001), respec-
tively, for patients with 0.1% to 9.9%, 10% to 19.9%, and
20% of the myocardium abnormal at stress (Fig. 2A).
In 2,101 patients with rest LVEF, Cox models including
the clinical variables with rest LVEF and the PET variables
(percent myocardium ischemic and percent myocardium
scarred), showed that a 10% higher rest LVEF was associ-
ated with a lower hazard of cardiac death (HR: 0.57; 95%
CI: 0.46 to 0.70; p  0.0001). After accounting for the
clinical variables and rest LVEF, there was an 84% higher
hazard of cardiac death (HR: 1.84; 95% CI: 1.40 to 2.41;
p  0.0001) for each 10% myocardium ischemic. For each
10% myocardium scarred, there was a trend toward a 23%
higher hazard of cardiac death (HR: 1.23; 95% CI: 0.96 to
1.56; p 0.09). The addition of percent myocardium ischemic
Clinical Characteristics From Multicenter PET PTable 1 Clinical Characteristics From Multic
P
0%
(n  3,109)
Age, yrs 62 13
Female, % 58.4
Body mass index, kg/m2 29.5 7
Hypertension, % 65.0
Diabetes, % 22.6
Dyslipidemia, % 59.8
Current smoker, % 18.7
Obesity, % 38.3
Reason for test: angina (chest pain
or dyspnea), %
66.4
Reasons for test: other, %* 33.6
Aspirin, % 45.7
Beta-blocker, % 39.9
History of MI, % 9
History of PCI, % 10.7
History of CABG, % 5
History of CABG or PCI, % 14.2
Rest heart rate, beats/min 69 12
Peak heart rate, beats/min 89 15
Rest systolic blood pressure, mm Hg 135 24
Peak systolic blood pressure, mm Hg 127 23
Percen
0%
(n  3,109)
0.1%–9.9%
(n  2,604)
0% 100% 27.8%
0.1%–9.9% 0% 72.2%
10%–19.9% 0% 0%
20% 0% 0%
Cardiac death, % 0.8 2.5
All-cause death, % 5.1 7.8
Values are mean  SD or %. Categorical variables were compared
statistic. Continuous variables were compared using an analysis of va
failure, preoperative testing, troponin elevation, syncope, and atrial or
CABG  coronary artery bypass grafting; MI  myocardial infarc
intervention; PET  positron emission tomography.and percent myocardium scarred to the clinical model includ-ing LVEF resulted in an increment in model chi-square value
from 110 to 127 (p  0.0001) and an increment in model
C-statistic from 0.844 to 0.875 (p  0.05).
Multivariable Cox models for the estimation of all-cause
death. The percent myocardium ischemic and percent
myocardium scarred were independent predictors of all-
cause death (Online Table 2).
Incremental prognostic value of PET MPI using con-
ventional and novel risk reclassification metrics. Tables
3 and 4 show the incremental value of PET MPI over
clinical risk factors using conventional parameters of model fit:
chi-square value, model Akaike information criterion value;
model global performance: change in C-statistic, integrated
discrimination improvement (IDI), and continuous NRI; and
model clinical value: NRI with categories. For cardiac death,
addition of the percent myocardium ischemic and percent
osis Registry in 7,061 Patientsr PET Prognosis Registry in 7,061 Patients
t Abnormal Myocardium on Stress MPI
%–9.9%
2,604)
10%–19.9%
(n  688)
>20%
(n  660) p Value
3 13 67 12 67 12 0.0001
44.0 30.7 26.4 0.0001
1 7 30 7 29 6 0.0001
67.9 76.5 72.1 0.0001
27.0 37.8 39.1 0.0001
63.7 73.1 74.2 0.0001
22.9 27.3 24.1 0.0001
48.8 42.9 37.1 0.0001
63.4 62.1 62.0 0.02
36.6 37.9 38.0 0.02
50.4 63.5 66.4 0.0001
47.4 67.0 67.7 0.0001
19.3 46.4 57.7 0.0001
17.8 31.5 32.4 0.0001
13.9 28.8 36.1 0.0001
28.0 50.7 57.0 0.0001
7 12 67 13 69 12 0.0001
6 16 81 16 82 16 0.0001
5 24 136 24 131 24 0.0001
9 22 127 27 120 23 0.0001
rmal Myocardium at Rest
10%–19.9%
(n  688)
>20%
(n  660) p Value
21.4% 9.5% 0.0001
53.9% 23.9%
24.7% 24.5%
0% 42.0%
6.1 9.7 0.0001
12.8 18.0 0.0001
chi-square likelihood ratio or linear-by-linear chi-square association
test. *Other reasons for the PET study included evaluation for heart
ular arrhythmias.
PI  myocardial perfusion imaging; PCI  percutaneous coronaryrognente
ercen
0.1
(n 
6
3
6
8
13
12
t Abno
using a
riance
ventricmyocardium scarred significantly improved the model fit, as
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all-cause death (Online Table 2) also showed improved model
fit and global performance but of a much smaller magnitude
compared with that of cardiac death.
To estimate the incremental clinical prognostic value, we
determined the net reclassification of risk after the addition
of the PET MPI information (percent myocardium is-
chemic and percent myocardium scarred) to the baseline
clinical information. As shown in Table 4 (cardiac death,
n  6,037), the majority of patients remained at the same
risk level (diagonal values from left upper to the right lower
cells) for events and nonevents.
Reclassification of cardiac death. The addition of percent
myocardium ischemic and percent myocardium scarred to a
baseline model with clinical factors resulted in significant
clinical incremental value for prediction of cardiac death.
The model IDI was 0.018 (95% CI: 0.01 to 0.03), with a
relative IDI of 33.6% (95% CI: 14.3% to 55.9%). The
continuous NRI was 54.0% (95% CI: 37.9% to 71.4%) for
annual risk categories of 1%, 1.0% to 2.9%, and 3.0%;
RI was 11.6% (95% CI: 2.1% to 21%) (Table 4). The
ddition of percent myocardium ischemic and percent
yocardium scarred to the clinical model more correctly
eclassified cardiac death in approximately 12% of patients.
he majority of the reclassifications were observed in the
ntermediate clinical risk group.
In patients with rest LVEF data, addition of percent
yocardium ischemic and percent myocardium scarred to
baseline model with clinical factors and rest LVEF
esulted in significant clinical incremental value for
rediction of cardiac death. The IDI was 0.017 (95% CI:
.002 to 0.037) and the relative IDI was 0.226 (95% CI:
.029 to 0.467). The continuous NRI was 0.504 (95%
Univariable Hazard Ratiosfor Cardiac Death (n  6,037)Table 2 Univariable Hazard Ratiosfor Cardiac Death (n  6,037)
Variable HR 95% CI for HR p Value
Age* 1.80 1.70–1.90 0.0001
Female 0.50 0.92–1.80 0.0001
History of hypertension 1.29 1.19–1.50 0.0001
History of diabetes 2.41 1.77–3.28 0.0001
History of dyslipidemia 0.81 0.59–1.10 0.0001
History of smoking 1.24 0.88–1.75 0.2
History of angina 0.66 0.48–0.89 0.007
Body mass index 0.97 0.95–0.99 0.006
History of PCI 1.57 1.10–2.30 0.02
History of CABG 2.36 1.66–3.36 0.0001
Aspirin 1.20 0.86–1.70 0.3
Beta-blockers 1.45 1.06–1.97 0.0001
Rest heart rate* 1.30 1.30–1.40 0.0001
Percent myocardium abnormal* 1.60 1.60–180 0.0001
Percent myocardium scarred* 1.90 1.70–2.10 0.0001
Percent myocardium ischemic* 1.70 1.50–1.90 0.0001
*Per 10-U change.
HR  hazard ratio; other abbreviations as in Table 1.I: 0.205 to 0.794), and NRI was 0.075 (95% CI: 0.008to 0.149) for annual risk categories of 1%, 1.0% to 2.9%
and 3.0%. The percent myocardium ischemic and
percent myocardium scarred provided incremental value
to the clinical model, which included rest LVEF, and
more correctly reclassified cardiac death in 8% of
patients.
For all-cause death, the NRI results also showed added
value of risk classification with PET MPI, although the
magnitude of reclassification was lower than that for cardiac
death (Online Table 2).
Discussion
The current report is the first multicenter registry to
examine prognosis in 7,061 patients undergoing pharmaco-
logical stress Rb-82 PET MPI. In the largest study to date,
our results demonstrated that for the prediction of cardiac
death and all-cause death, an abnormal PET MPI provided
significant incremental prognostic value over the clinical
factors. Patients with a severely abnormal stress PET MPI
had almost a 5-fold higher hazard of cardiac death com-
pared with patients with a normal PET MPI, even after
accounting for clinical risk markers. Also, an abnormal PET
MPI along with clinical risk markers provided significant
risk reclassification in 12% of patients, confirming the
clinical utility of PET MPI. This study provided the initial
strong evidence that the magnitude of scar and ischemia on
PET MPI can be a powerful tool for risk reclassification of
patients with known or suspected CAD. Importantly, this
multicenter registry provided an enriched cohort of patients
with geographic diversity imaged on a variety of imaging
devices, making the results much more generalizable than
prior single-center studies.
Risk reclassification is a relatively novel concept that has
been applied to the assessment of other risk markers such as
calcium score (13), C-reactive protein (14), and more
recently single-photon emission computed tomography
(SPECT) MPI (15) and coronary flow reserve by quantita-
tive PET MPI (8,16,17). To our knowledge, this is the first
study assessing risk reclassification with rest and stress
perfusion defects on PET MPI compared with clinical
factors. By demonstrating significant risk reclassification for
every 10% ischemic myocardium, this study confirmed a
threshold of 10% ischemic myocardium as significant for
risk stratification with PET MPI, similar to that previously
established with SPECT MPI (18). The results of this study
provided evidence that the magnitude of ischemia and scar
on PET MPI provides for a significant improvement (large
effect size based on a continuous NRI 0.540) (12) in clinical
risk stratification; risk was reclassified more appropriately in
11.6% of the patients for cardiac death, potentially aiding in
management decisions. Further, in exploratory analyses, it
appeared that the knowledge of magnitude of ischemia on
PET MPI resulted in reclassification of 7.5% of patients
compared with the clinical variables including rest LVEF.
The NRI can provide an excellent measure for assessing the
180 Dorbala et al. JACC Vol. 61, No. 2, 2013
Prognostic Value of PET MPI: A Multicenter Registry January 15, 2013:176–84clinical utility of a novel risk marker (11,15). The NRI value
of a novel risk marker can be compared with that of another
marker within the same patient cohort. However, direct
comparison of the NRI values between different study
cohorts may be challenging because of the inherent differ-
ences in patient risk characteristics and clinical variables
Figure 1 Unadjusted Hazard of Events by Percent Myocardium
Hazard of (A) cardiac death (6,037 patients, 169 cardiac deaths) and (B) all-caus
positron emission tomography (PET) myocardial perfusion imaging (MPI) and increa
abnormality. Rb-82  rubidium-82.used in the respective studies. Hence, whether the clinicalutility of rest or stress perfusion defects by PET MPI is
superior to or similar to that published with SPECT MPI
on the basis of NRI cannot be definitively determined.
Also, it is important to recognize that although reclassi-
fication of risk suggests that management and outcomes
would be potentially altered based on the results of the
rmal on Vasodilator Stress Rb-82 PET
th (7,061 patients, 570 all-cause deaths) was lowest in patients with normal
radually in patients with minimal, mild, moderate, and severe degrees of scanAbno
e dea
sed gPET MPI study, larger prospective clinical trials would
classifi
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ment and outcome.
Although several single-center studies have shown that
relative PET, quantitative PET MPI, and PET assessed
coronary flow reserve (8,16,17) provide risk stratification for
cardiovascular outcomes, data about improved risk reclassi-
fication with PET MPI are limited (8,16). The current
study demonstrated that relative PET MPI provided for
improved risk reclassification of 12% of patients, over
clinical variables, whereas recent studies have shown that
coronary flow reserve assessed by quantitative PET MPI
provides additional risk reclassification of 10% to 11% of
patients (8,16). The addition of measures of atherosclerosis
such as calcium score (19) or CT coronary angiography (20)
may provide additional risk stratification to relative PET
MPI. However, it remains to be seen whether measures of
coronary atherosclerosis provide incremental reclassification
of risk compared with relative PET MPI.
PET MPI offers several clinical advantages compared
with SPECT MPI (21); image quality is superior, test
specificity for the diagnosis of obstructive CAD is higher,
and identification of scar and ischemia is better with PET
MPI. As shown recently, ischemia and scar can modulate
the prognostic value of MPI (22). PET MPI is particularly
advantageous in high clinical risk cohorts such as those
Multivariable Cox Proportional Hazard Models Estimating Cardiac DTable 3 Multivariable Cox Proportional Hazard Models Estimat
Variable
Clinical Model
HR 95% CI for HR
Age in deciles 2.00 1.72–2.33
Female 0.49 0.35–0.68
Body mass index 0.99 0.96–1.01
History of hypertension 1.05 0.74–1.49
History of diabetes 2.28 1.65–3.14
History of dyslipidemia 0.70 0.51–0.96
History of smoking 1.69 1.19–2.40
History of angina 0.69 0.50–0.93
Beta-blocker 1.33 0.96–1.84
Rest heart rate* 1.40 1.26–1.56
History of PCI 1.47 1.01–2.13
History of CABG 1.32 0.92–1.90
Percent myocardium ischemic*
Percent myocardium scarred*
Clinical
AIC 2,6
Chi-square value 2
C-statistic 0.805 (0.7
IDI
Relative IDI
NRI continuous
NRI categories
*Per 10-U change.
AIC  Akaike information criterion; IDI  integrated discrimination improvement; NRI  net reundergoing pharmacological stress testing and patients withheart failure or obesity (21). Importantly, the incremental
clinical value of PET MPI is attained at a significantly lower
estimated effective radiation dose to the patients (approxi-
mately 2.0 to 3.7 mSv [23,24] with Rb-82 MPI compared
with 10 to 12 mSv with technetium-99m MPI [25]) and at
a much faster pace compared with SPECT MPI. However,
when compared with SPECT, the evidence supporting the
clinical utility of PET MPI is limited. Although the
prognostic value of SPECT MPI has been described in
several tens of thousands of patients, the prognostic value of
PET MPI is only available in several thousands of patients.
The results of the current study are critical to advance the
field and guide more effective use of PET MPI in clinical
practice.
Likewise, the prognostic value of CT coronary angiogra-
phy is currently being established. However, although CT
coronary angiography provides information about the nature
and anatomic extent and severity of coronary atherosclero-
sis, SPECT and PET MPI provide information about
myocardial blood flow; PET MPI takes into account un-
derlying CAD, collateral flow, myocardial adaptation to
wall stress, and other factors and can be used in patients
with renal insufficiency.
Study strengths and limitations. This was a large multi-
center registry composed of patients from 4 medical centers
(n  6,036)ardiac Death (n  6,036)
Clinical  PET Model
p Value HR 95% CI for HR p Value
0.0001 1.98 1.70–2.31 0.0001
0.0001 0.55 0.39–0.77 0.0005
0.28 0.99 0.96–1.01 0.31
0.79 1.14 0.80–1.62 0.46
0.0001 2.13 1.55–2.94 0.0001
0.0001 0.64 0.47–0.88 0.006
0.003 1.69 1.19–2.39 0.004
0.016 0.73 0.54–1.00 0.05
0.09 1.26 0.87–1.67 0.16
0.0001 1.34 1.19–1.50 0.0001
0.04 1.34 0.91–1.941 0.13
0.14 1.04 0.72–1.50 0.82
1.34 1.15–1.57 0.0003
1.57 1.38–1.78 0.0001
parison of the Clinical and Clinical  PET Models for Cardiac Death
l Clinical  PET Model
2,556
275
38) 0.839 (0.809–0.869)
0.018 (0.01–0.03)
0.336 (0.143–0.559)
0.540 (0.379–0.714)
0.116 (0.021–0.210)
cation improvement; other abbreviations as in Tables 1 and 2.eathing C
Com
Mode
05
21
72–0.8with the corresponding strengths, limitations, and biases.
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Prognostic Value of PET MPI: A Multicenter Registry January 15, 2013:176–84Cardiac death was analyzed in only 6,037 patients. Renal
failure was not included in this analysis, reproducibility of
scan interpretation among the medical centers was not
measured, and the prognostic value of PET in patients
without angina or dyspnea was not specifically studied.
Also, LVEF was not available in all of the patients, and
inclusion of LVEF may potentially alter the relation be-
Figure 2 Risk-Adjusted Hazard of Events by Percent Myocardiu
Hazard of (A) cardiac death (6,037 patients, 169 cardiac deaths) and (B) all-caus
with normal PET MPI and increased gradually in patients with minimal, mild, modetween scarred myocardium and outcomes. Data on earlyrevascularization were not available from all of the centers;
therefore, we were not able to test whether patients with
abnormal imaging findings would be more likely to benefit
from revascularization. However, the inclusion of patients
with early revascularization may serve to strengthen our
results because revascularization would be expected to at-
tenuate the relation between PET MPI and clinical out-
normal on Vasodilator Stress Rb-82 PET
th (7,061 patients, 570 all-cause deaths) was lowest in patients
nd severe degrees of scan abnormality. Abbreviations as in Figure 1.m Ab
e dea
rate, acomes. Last, the majority of the perfusion studies were
11
1
1
1
1
(95% C
183JACC Vol. 61, No. 2, 2013 Dorbala et al.
January 15, 2013:176–84 Prognostic Value of PET MPI: A Multicenter Registryscored visually, but one site used automated software anal-
ysis. Automated quantitation of MPI is well validated for
risk assessment and comparable to visual analyses (26). Yet,
the multisite registry design overcomes the limitations
inherent to data from single centers in terms of homogene-
ity of patient population and data spanning a decade of
imaging, further expanding the diversity and generalizability
of the study results. The large study cohort allowed us
adequate power to study measures of risk reclassification,
which would not be possible by data from any of the
individual centers.
Conclusions
Despite widespread clinical use of PET MPI for its superior
diagnostic accuracy and safety profile, the evidence for
incremental risk stratification with PET MPI is limited.
The results of this large multicenter registry demonstrated
that in patients with known or suspected CAD, Rb-82 PET
MPI provided powerful and incremental risk stratification.
Assessment of the magnitude of ischemia and scar on PET
MPI adds to the reclassification of risk for cardiac death in
1 of 9 patients undergoing clinical PET MPI.
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